IP Library Granted Patent US 9,458,222
Granted Patent B2
US 9,458,222 · App. 13/179,399 · Granted Oct 4, 2016

Method of producing recombinant ADAMTS13 in cell culture

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,458,222
App. No.
13/179,399
Granted
Oct 4, 2016
Kind
B2
Abstract

Among other aspects, the present invention relates to cell culture conditions for producing high molecular weight vWF, in particular, highly multimericWF with a high specific activity and ADAMTS13 with a high specific activity. The cell culture conditions of the present invention can include, for example, a cell culture medium with an increased copper concentration and/or cell culture supernatant with a low ammonium (NH 4 + ) concentration. The present invention also provides methods for cultivating cells in the cell culture conditions to express high molecular weight vWF and rA13 having high specific activities.

Claims (17)

1. A method for producing a recombinant ADAMTS 13 (rA13) composition, the method comprising the steps of:

(a) providing a protein free, chemically-defined, basal cell culture media;

(b) supplementing the basal cell culture media with copper to provide a final copper concentration of from 2 μg/L to 4 μg/L;

(c) providing one or more mammalian cells comprising a nucleic acid encoding a rA13 protein;

(d) culturing the one or more mammalian cells in the copper supplemented cell culture media such that rA13 is expressed and excreted from the cells into a culture supernatant, wherein the NH 4 + content of the cell culture supernatant is maintained at a concentration below 10 mM; and

(e) recovering at least a portion of the culture supernatant,

wherein the mammalian cell density is maintained at less than 4.0×10 6 cells per mL during the step of culturing the one or more cells; and

wherein at least 1500 Units FRETS-VWF73 activity per liter supplemented basal cell culture media per day is present in the recovered culture supernatant.

2. The method of claim 1 , wherein the mammalian cells are CHO cells.

3. The method of claim 1 , wherein culturing the one or more mammalian cells comprises batch cultivation of the cells.

4. The method of claim 1 , wherein culturing the one or more mammalian cells comprises continuous cultivation of the cells.

5. The method of claim 4 , wherein the continuous cultivation of mammalian cells is performed in chemostatic mode.

6. The method of claim 4 , wherein the continuous cultivation of mammalian cells is performed in perfusion mode.

7. The method of claim 1 , wherein the one or more mammalian cells is cultured in at least 100 L of the supplemented basal cell culture media.

8. The method of claim 1 , wherein the mammalian cell density is maintained at between 3.0×10 6 cells per mL and 4.0×10 6 cells per mL during the step of culturing the one or more cells.

9. The method of claim 1 , wherein at least 2000 Units FRETS-VWF73 activity per liter supplemented basal cell culture media per day is present in the recovered culture supernatant.

10. The method of claim 1 , wherein the NH 4 + content of the mammalian cell culture supernatant is maintained at a concentration below 5 mM.

Assignments (4)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 31, 2021
From: BAXALTA GMBH; BAXALTA INCORPORATED
To: TAKEDA PHARMACEUTICAL COMPANY LIMITED
Reel/Frame 055189/0238 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 17, 2015
From: BAXTER INTERNATIONAL INC.
To: BAXALTA GMBH; BAXALTA INCORPORATED
Reel/Frame 036368/0311 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 17, 2015
From: BAXTER HEALTHCARE SA
To: BAXALTA GMBH; BAXALTA INCORPORATED
Reel/Frame 036369/0367 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 26, 2011
From: GRILLBERGER, LEOPOLD; REITER, MANFRED; FLEISCHANDERL, DANIEL; BRAMBERGER, GREGOR
To: BAXTER INTERNATIONAL INC.; BAXTER HEALTHCARE S.A.
Reel/Frame 027125/0351 →